In This Article:
Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (NYSE: MDT), one of the largest and most diversified medical device makers.
Here's why this is the one healthcare stock I own and why I think it will help set me up for life -- and may do the same for you too if you buy it.
I'm a die-hard dividend investor
One of the signs of dividend greatness is a company that has increased its dividend year in and year out for decades. That can only be accomplished if a company has a strong business model that gets executed well in both good times and bad. That said, even great companies go through bad times, which is when I most like to buy them. My preferred tool for finding companies that have fallen on hard times is looking for stocks with historically high dividend yields.
Medtronic has increased its dividend annually for 47 consecutive years, the third-longest streak in the healthcare sector. Its nearly 3.1% dividend yield is near the high end of the company's historical yield range. I'm not going to claim to be an expert on the healthcare sector, but I am confident that my investment in Medtronic is going to set me up for life, or at least for a lifetime of reliable income.
Medtronic is an industry leader
One of the big reasons why I avoid most healthcare stocks is that the pace of innovation is swift, and I just don't have the expertise (or the time) to keep up with the sector's ongoing evolution. But Medtronic isn't a tiny upstart; it is a medical device Goliath with leading positions in cardiac care, neuroscience, surgery, and diabetes management. It is most certainly doing cutting-edge research, but it is also large enough to act as an industry consolidator.
That means I don't need to worry about change. Medtronic is on top of it and ensuring that it remains at the cutting edge, even if that means buying its way into new technologies.
So, why is the stock unloved? The answer is that its portfolio had become bloated and its business a bit unwieldy. That happens over time, particularly if acquisitions are a key part of a company's business model. The solution in almost every case is to restructure the business, sell non-core assets, and work on increasing efficiencies. This is what Medtronic is doing. It has been a slow process, but it is starting to show results.